Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn,☆☆

https://doi.org/10.1016/S0022-3476(99)70462-2Get rights and content
Under a Creative Commons license
open archive

Abstract

Subcutaneous fat necrosis of the newborn (SCFN) is characterized by indurated violet skin nodules and, occasionally, life-threatening hypercalcemia. Current treatments of patients with SCFN-related hypercalcemia are often only partially successful and may be associated with prolonged hypercalcemia. We now report the use of etidronate, a bisphosphonate, to control hypercalcemia in an infant with SCFN. (J Pediatr 1999;134:349-51)

Abbreviations

SCFN
Subcutaneous fat necrosis of the newborn.

Cited by (0)

Reprint requests: Alan M. Rice, MD, Yale Pediatrics, Endocrinology, PO Box 208081, 464 Congress Ave, New Haven, CT 06520.

☆☆

0022-3476/99/$8.00 + 0  9/22/95109